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β cells may participate and contribute to their own demise during Type 1 diabetes (T1D). Here
we report a role of their expression of Tet2 in regulating immune killing. Tet2 is induced in
murine and human β cells with inflammation but its expression is reduced in surviving β cells.
Tet2-KO mice that receive WT bone marrow transplants develop insulitis but not diabetes
and islet infiltrates do not eliminate β cells even though immune cells from the mice can
transfer diabetes to NOD/scid recipients. Tet2-KO recipients are protected from transfer of
disease by diabetogenic immune cells.Tet2-KO β cells show reduced expression of IFNγ-
induced inflammatory genes that are needed to activate diabetogenic T cells. Here we show
that Tet2 regulates pathologic interactions between β cells and immune cells and controls
damaging inflammatory pathways. Our data suggests that eliminating TET2 in β cells may
reduce activating pathologic immune cells and killing of β cells.
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Type 1 diabetes (T1D) is a chronic autoimmune conditionthat occurs over years after the first signs of autoimmunity,which are represented by the appearance of autoantibodies.
With the improvement in the sensitivity of measurement of
C-peptide and the availability of tissue sections from individuals
who have died with T1D, it has become clear that not all β cells
are destroyed by autoimmunity. Even 50 years after the diagnosis
of T1D about 2/3 of patients still have detectable levels of
C-peptide indicating residual β cells1. Moreover, the increased
relative levels of proinsulin suggest dysfunctional but persistent β
cells2. The reasons why some β cells survive and others succumb
to autoimmune killing are not certain.
There is growing evidence showing β cells are not passive
bystanders of their own destruction, but instead participate and
contribute to their own demise in the pathogenesis of auto-
immune diabetes. Genome-wide association studies (GWAS)
show that >50% of gene loci associated with T1D are expressed in
β cells. These studies, coupled with emerging molecular evidence
that β cells are impaired by gain-of-function or loss-of-function
of these loci, suggest an active role for the β cell in eliciting its
own demise3–6. In addition to the intrinsic features of β cells,
accumulating data suggest that β cells can control pathways of
immune tolerance. β cells are required to initiate diabetes auto-
immunity. Spleen cells from β-cell-deprived NOD mice cannot
transfer diabetes although they maintain immune competency.
Furthermore, “diabetogenic” spleen cells showed a reduced
capacity to transfer diabetes after transient “parking” in β-cell-
deprived mice7. The islet cell mass plays a critical role in diabetes
—surgical removal of 90% of pancreatic tissue before the onset of
insulitis induced a long-term protection in NOD mice. Lym-
phocytes from pancreatectomized diabetes-free mice exhibited a
low response to islet cells8. Curiously, in NOD mice and human
T1D, autoimmunity does not extend to cells that share antigens
with β cells, particularly cohabitating endocrine islet cells and
neuronal cells that express GAD and IA-2. It is thus likely that
features of β cells that cause expression of autoantigens and their
presentation under conditions for T cell activation are pre-
requisites to the development of autoimmune lesions. Thus, the
interplay between β cells and immune cells determine the out-
come of autoimmunity.
β cells are also known to be intrinsically vulnerable to killing,
and are more prone than other islet endocrine cells, to death
under ER and immune stress conditions9,10. Early physiological β
cell death triggers priming of autoreactive T cells by dendritic
cells in pancreatic lymph nodes (pLNs)11,12. Thompson et al.
described a subpopulation of β cells that become senescent and
actively promotes the immune-mediated destruction process13.
Recently Lee et al. reported that modulating the unfolded protein
response (UPR) in NOD β cells by deleting the UPR sensor IRE1α
prior to insulitis induced transient dedifferentiation of β cells,
resulting in substantially reduced islet immune cell infiltration
and β cell apoptosis and protection from diabetes14. When we
previously analyzed β cells during the progression of diabetes, we
identified a subset of β cells with dedifferentiated features such as
reduced expression of Pdx1, Nkx6.1, MafA, and Ins1, Ins2 as well
as β cell autoantigens, and those cells were resistant to immune-
mediated killing15.
Among the mechanisms that might account for the changes of
β cells in response to stressors are epigenetic changes involving
silencing or activation of genes as a consequence of signaling by
factors such as inflammatory cytokines. Stefan-Lifshitz et al.
associated DNA hydroxymethylation by IFNα16. In our previous
studies, we found epigenetic changes in β cells from NOD mice
that led to methylation marks in Ins1 and Ins2 and reduced gene
transcription and similar changes in INS when human islets were
cultured with inflammatory cytokines17. The increased expression
of Dnmts, we postulated resulted in methylation of CpG sites in
the insulin genes and repression of gene transcription17.
The responses to inflammation and epigenetic modifications
may be linked by the activity of the ten-eleven translocation (Tet)
methylcytosine dioxygenase family members. Zhang et al. showed
that Tet2 is required to resolve inflammation by recruiting Hdac2
to repress IL-6. In melanoma and colon tumor cells deletion of
Tet2 reduced chemokine expression and tumor-infiltrating lym-
phocytes, enabling tumors to evade antitumor immunity and to
resist anti-PD-L1 therapy18. Whereas enhancing TET activity
with ascorbate/vitamin C increased chemokines, tumor-
infiltrating lymphocytes, and antitumor immunity18,19. In pri-
mary microglial cells lacking Tet2, there is inhibition of IL-6
release and TNF-α after LPS treatment20. Deletion of Tet2 in
T cells decreased their cytokine expression, associated with
reduced p300 recruitment21. Lastly, a role for Tet2 in cell survival
has also been suggested as Tet2-KO hematopoietic stem and
progenitor cells have reduced apoptosis22.
To understand how epigenetic modifications may change β
cells and affect immune/β cell interactions during autoimmune
diabetes, we studied the role of Tet2 and epigenetic changes in
human and murine β cells during the autoimmune attack. Here
we show that Tet2 regulates pathologic interactions between β
cells and immune cells in humans with immune infiltrates in the
pancreas and with diabetes and in mice with autoimmune dia-
betes by controlling damaging inflammatory pathways.
Results
Induction of Tet2 in murine β cells during the progression of
autoimmune diabetes. We first studied Tet gene expression in
whole islets and β cells from NOD mice, a model of human T1D.
Soon after weaning, at 3–4 weeks, a period of time that has been
associated with the initiation of autoimmunity, we found a
modest increase in expression of Tet1 but substantially increased
expression of Tet2 in whole islets (Fig. 1a) in NOD mice but not
immune-deficient NOD/scid mice of the same age. We identified
these changes in Tet genes in β cells from 8- and 11-week-old
NOD mice by enriching for β cells by sorting on Zinc+ and
TMRE+ islet cells. (Fig. 1b). Because of the profound increase in
Tet2 expression in NOD β cells, we focused our studies on this
epigenetic regulator. We examined individual inflammatory
cytokine as well as cytokine combinations which have been found
to mediate β cell killing during the pathogenesis of autoimmune
diabetes, on Tet2 induction in islets from B6 mice23. IL-1β or
IFNγ alone and combinations of IL-6/IL-17A and TNFα/ IL-1β/
IFNγ could induce Tet2 gene transcription in the islets and β cells
(Fig. 1c) as well as increased protein expression, identified by
FACS (Fig. 1d).
Expression of TET2 in human β cells. We analyzed TET2
expression in human islets in different inflammatory settings by
immunohistochemistry. In control pancreases, TET2 expression
was seen outside of the islets among exocrine tissue (Fig. 2a(a)).
However, there was increased TET2 expression in the nuclear and
cytoplasm in β cells from a patient with autoimmune pancreatitis
(with cellular immune infiltrates) (Fig. 2a(b)), as well as a patient
with T1D autoantibodies but not diagnosed with T1D
(Fig. 2a(c)), and patients with recent-onset T1D (Fig. 2a(d)). The
expression of TET2 in β cells was associated with inflammatory
lesions since we did not identify it in the β cells in the pancreas
from patients with chronic pancreatitis in which infiltrating
immune cells were not found (Fig. 2a(f)). Interestingly, we also
did not identify TET2 staining in the remaining singular β cells in
the pancreas from patients with long-established T1D who did
not have detectable autoantibodies or insulitis (Fig. 2a(e)). The
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fluorescence intensity of TET2 staining in β cells in different
clinical conditions was quantified in Fig. 2b. The expression of
TET2 in β cells in autoimmune pancreatitis and T1D onset plus
some autoantibody+ individuals was significantly higher com-
pared to conditions without inflammation. Our findings were
consistent with our studies with murine islets and suggested that
inflammatory cytokines could induce TET2 expression. We,
therefore, analyzed TET2 expression in human islets (Supple-
mentary Table 1) that were cultured with individual cytokine or
cytokine combinations and found increased TET2 gene expres-
sion in IL-1β or IFNγ alone as well as IL6/IL-17A and TNFα/IL-
1β/IFNγ combinations group (Fig. 2c).
These observations suggest that TET2 expression is induced by
inflammatory cytokines and suggest a permissive but not
sufficient role for β cell killing since we found increased TET2
in β cells from patients with autoimmune pancreatitis that do not
develop diabetes. However, we noted that not all of the β cells in
patients with T1D or in the autoantibody+ relatives were
TET2+. Moreover, in samples from patients with long-standing
T1D, we identified β cells by insulin staining, consistent with
reports of residual β cells even in long-standing patients, but we
did not find TET2 expression in those β cells (Fig. 2a(e)).
Resistance of Tet2-KO β cells to immune killing. To understand
the role of Tet2 in the inflammatory responses of β cells, we bred
Tet2-KO NOD mice. Tet proteins are known to play an impor-
tant role in cell development24 and Dhawan et al. reported that
deletion of Tet2 in the pancreatic lineage results in improved
glucose tolerance and β cell function (https://doi.org/10.2337/
db18-50-OR). Therefore, we first characterized β cell function,
islet cells, and gene expression from Tet2-KO B6 mice. The
glucose tolerance to IPGTTs and morphology of the islets were
indistinguishable between the KO and wild-type (WT) mice
(Supplementary Fig. 1a, b). There were small but significant
differences in the proportion of β and α cells in the KO mice as
well as in the MFI of insulin and Pdx1 but the expression of Ins1,
Ins2, Nkx6.1, ChgA, and Pdx1 were similar to WT β cells (Sup-
plementary Fig 1c–e). Overall these findings suggest that there
may be subtle differences in the composition of islets from KO
and WT mice but not detectable functional abnormalities of Tet2-
KO β cells.
We backcrossed the KO allele to NOD for more than 14
generations. The Tet2-KO NOD mice did not develop sponta-
neous diabetes whereas the median time to diabetes was 17 and
23 weeks in their WT and HET littermates (Supplementary
Fig. 2).
Because Tet2 is involved in the development and function of
immune cells, we transplanted bone marrow (BM) from WT
NOD mice into WT or Tet2-KO recipients to eliminate any
impact of Tet2 loss in immune cells. The Tet2-KO mice had a
markedly reduced incidence of diabetes (median survival
undefined) compared to WT recipients of NOD WT BM (median
survival= 11 weeks) (p < 0.0001) (Fig. 3a). This was not due to
the lack of immune infiltration in KO recipients. Figure 3b shows
the frequencies of immune and nonimmune (CD45+ and −,
respectively) from BMT recipients ages 8 to 20 weeks. We
assessed the insulitis from KO BMT recipients at 20 weeks and
analyzed 112 islets using a 4 point score (0–3). Forty-eight islets
are score 0 (43%), 25 are score1 (22%), 26 are score 2 (23%), and
13 are score 3 (17%). At the same level of immune cell infiltrates,
Fig. 1 Increased Tet2 expression in islet β cells during diabetes progression in nonobese diabetic (NOD) mice. Transcription analysis of the Tet genes in
a handpicked islets from NOD and NOD/scid mice of different ages, b enriched β cells (Zn+ TMRE+) sorted from NOD mice of different ages, and c islets
from B6 mice following 24-h culture with indicated cytokines, 10 ng/ml each. RNA was recovered and Tet genes were measured by qRT-PCR. The Ct
values were normalized to Actb mRNA levels (Delta Ct= (Ct of Actb− Ct of target gene)+ 20). Data show the mean ± SD of three experiments, each with
3–6 mice. Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparisons test in a, b and one-way ANOVA with Dunnett’s
multiple comparisons test in c. d Histogram comparing Tet2 protein level in β cells from 4-week-old as well as new-onset diabetic NOD mice analyzed by
FACS. β cells from NOD Tet2-knock out (KO) mice were included as a negative control for Tet2 staining. Tet2+ β cells were identified by intracellular
staining with antibodies against insulin and Tet2. Data were representative of three experiments, n= 3–5 for each experiment. (Gray histogram= β cells
from NOD KO mice, Blue=wild-type NOD mice at 4 weeks of age and red= at diagnosis with hyperglycemia).
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there were fewer surviving β cells in the WT recipients
(r=−0.82, p < 0.0001) that was not seen in the Tet2-KO
recipients (p= 0.1447). It was possible that autoreactive cell
development was impaired in the Tet2-KO recipients. However,
we found a similar frequency of IGRP-reactive CD8+ T cells in
the WT and Tet2-KO BM recipients (Fig. 3c). In addition, we
transferred splenocytes from KO bone marrow transfer (BMT)
recipients that did not have diabetes, 11–14 weeks after the BMT,
or from diabetic WT BMT recipients, into NOD/scid mice. These
NOD/scid recipients developed diabetes at a similar rate (Fig. 3d),
indicating that autoimmune T cells are present in nondiabetic
Tet2-KO BMT recipients.
To further understand the nature of the resistance of β cells to
killing, we transplanted islets from 5–6-week-old KO vs WT mice
under the kidney capsules of 6-week-old NOD WT recipients.
Two weeks after the transplant, and in addition, gave 1 × 107
diabetogenic splenocytes to synchronize the development of
diabetes. Recipients were followed for the development of
hyperglycemia which required the killing of both the endogenous
and the transplanted islets. The time to diabetes onset in the
recipients of KO islets was delayed by 4.5 weeks (median
survival= 19.5 weeks) compared to recipients of NOD WT islets
(median survival= 15 weeks) (p < 0.0001). All of the 11 recipients
of WT islets developed diabetes whereas, at 25 weeks, three of the
12 recipients of KO islets were diabetes-free (Fig. 3e). When the
graft-bearing kidney was removed, there was rapid hyperglyce-
mia, indicating that the transplanted islets were the source of
insulin in the mice and that the endogenous WT β cells in the
recipients had been destroyed. The Tet2-KO β cells could be
killed by chemical means (i.e., streptozotocin) in vivo (Supple-
mentary Fig. 3), suggesting that the resistance of the KO β cells to
killing was to immune mechanisms.
To directly assess the effects of inflammatory mediators on
Tet2-KO β cells, we cultured single islet cells with inflammatory
cytokines that cause β cell death and found increased survival of
Tet2-KO vs WT β cells (Fig. 3f). The resistance of the KO β cells
was greater than α cells (Fig. 3f). Second, we cultured WT NOD/
scid and Tet2-KO β cells with purified islet infiltrates from
prediabetic WT NOD mice and found the greater killing of the
WT vs Tet2-KO β cells (Fig. 3g).
Fig. 2 Induction of TET2 in human β cells with inflammation. a Expression of TET2 protein in human β cells in vivo in pancreas from a healthy control
subject (a), patient with autoimmune pancreatitis (b), a nondiabetic individual with autoantibodies to GADA and ZnT8 who is a relative of a patient with
Type 1 diabetes (c), a patient with recent-onset T1D (d), patient with Type 1 diabetes for 15 years without detectable autoantibodies (e), and (f) a patient
with chronic pancreatitis. The sections were stained with anti-TET2 (red) and anti-insulin (green) as well as anti-CD45 (Cyan) antibody. DAPI (blue) stains
the cell nucleus. The merged staining is shown. Arrows indicate TET2+ β cells in b, c, and d and β cells in e and f. Data were from normal individuals
(n= 8), donors with autoimmune pancreatitis (n= 5), nondiabetic donors who were autoantibody+ (n= 7), and C-peptide+ patients with T1D of
relatively short duration (n= 7). Scale bars: 25 μm. b Image J quantification of the fluorescence intensity of TET2 staining in islets studied in Fig. 1a. Twenty
islets per condition were looked at, with three–seven donors for each condition. Different clinical conditions were compared to a healthy individual.
Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple comparisons test. c Human islets were cultured with individual or
combined cytokines as indicated for 24 h before transcription analysis of TET2 gene by qRT-PCR. The fold of TET2 mRNA induced by cytokines relative to
islets cultured in media alone is shown. Data were mean ± SD from five experiments, each with 2000–8000 islet equivalents (IEQ) from nondiabetic
individuals (Fold vs islets cultured in media alone. Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple comparisons test.
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Fig. 3 β cells lacking Tet2 are protected from immune killing in vivo and in vitro. a Diabetes incidence in WT or KO recipients of WT bone marrow.
Statistical analysis was performed using Log-rank curve comparison. n= 17 for each group. b Relationship between cellular infiltrates and loss of β cells in
WT and Tet2-KO recipients of WT bone marrow. The frequency of the intra-islet CD45+ cells and β cells (insulin+) analysed by FACS. Simple linear
regression was used together with a two-side correlation test for statistical analysis. For WT recipients, Pearson r=−0.82, p < 0.0001; for Tet2-KO
recipients, p= ns. Each circle/square represents one mouse (WT, n= 47; KO, n= 36). c Frequency of IGRP-reactive CD8+ T cells in the spleen analysed
by FACS. Fourteen weeks after transplant, splenocytes from KO or WT BMT recipients were stained with NRPV7 tetramer to identify IGRP-reactive
CD8+ T cells. A single pair, representative of three experiments are shown. d Transfer of diabetes into NOD/scid mice with 107 splenocytes from either
nondiabetic KO or hyperglycemic WT BMT recipients 12 weeks post-BMT. Data were from two experiments, each with pooled splenocytes from two KO
and two WT BMT recipients. Statistical analysis was performed using Log-rank curve comparison. e Diabetes incidence in islet transplant recipients from
either WT or Tet2-KO NOD. About 250–300 pooled islets from 5–6-week-old WT or KO NOD mice were transplanted under the kidney capsule of 6-
week-old WT NOD followed by transfer of 107 diabetogenic splenocytes. The median survival time in WT is 15 vs 19.5 weeks in KO recipients. Statistical
analysis was performed using Log-rank curve comparison (WT, n= 11; KO, n= 12). f Islet β cell survival during culture with cytokines. Single islet cells from
WT or Tet2-KO B6 mice were cultured with the indicated cytokines for 12 h and the live cell percentage was determined in β as well as α cells (identified by
insulin and glucagon staining) by FACS. Results are mean ± SD of three experiments, n= 6 each. Statistical analysis was performed using two-way ANOVA
with Tukey’s multiple comparisons test. g β cell survival during culture with diabetogenic islets infiltrates. Sorted β cells from either WT NOD/scid or Tet2-
KO NOD mice were cultured overnight with islets infiltrates sorted from the same prediabetic WT NOD at a ratio of 1:5. Results are mean ± SD of three
experiments, n= 5–6 each. Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple comparisons test.
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These initial observations suggested that a subpopulation of β
cells that survive immune attack have reduced Tet2 despite the
general increase in expression that we had observed during
disease progression in vivo, and in human β cells that were
exposed to inflammatory cytokines. In our previous studies in
NOD mice, we identified a subpopulation of β cells, characterized
by reduced insulin granularity, increased expression of “stem-
like” genes, and reduced β cell markers such as Pdx1, Nkx6.1, and
MafA that was resistant to immune-mediated killing15. Therefore,
we analyzed Tet2 expression among these subpopulations of β
cells from NOD mice. We found that Tet2 levels were higher in
the normal (i.e., “top”) β cells that we showed succumbed to
immune killing during the progression of the autoimmune
disease when compared to the hypogranular (i.e., “bottom”) cells
that survived cytokine and immune cell-mediated killing
(Supplementary Fig. 4).
Immune responses are modulated by Tet2-deficient islet cells.
We analyzed the islet infiltrates from the WT and KO recipients
of WT BM, 8 weeks after transplant to understand how the Tet2-
KO islet cells changed the immune responses. The frequency of
infiltrating cells was similar in the KO and WT islets (Supple-
mentary Fig. 5). We analyzed gene expression by NanoString
(pan-immunology panel) and found differential expression of 189
of 770 genes. There was decreased expression of genes associated
with kinase signaling needed for T cell activation such as Stat3,
Jak2, Smad3, Nfkb, and Mapk, reduced expression of molecules
associated with cell–cell interaction, as well as T cell function such
as Cd137, Gzmm, and Gzmk in addition to a panel of reduced
cytokines (Fig. 4a). In addition, the infiltrating cells from KO
recipients show increased expression of pro-cell death genes such
as Bax, Casp3, Casp8, and Tnfsf10 (Trail) and reduced pro-
survival gene Bcl2. Pathway analysis (with Ingenuity Pathway
Analysis (IPA)) identified differences in inflammatory responses
implicating 91 genes. Other affected pathways included cell-to-
cell signaling and interaction, cellular function and maintenance,
growth and proliferation, and movement which were significantly
decreased in immune cells from KO recipients. Th1 and Th2
activation pathways were reduced in KO recipients as well as
pathways of cell trafficking (Table 1). There were phenotypic
difference between the infiltrating T cells in the KO and WT
mice. To confirm these findings, we analyzed immune cells from
the draining (pancreatic) lymph nodes from KO and WT BMT
recipients of WT BM by FACS. The T cells from the KO reci-
pients showed reduced frequencies of total T cells and increased
frequency of B cells (Fig. 4b). In addition, there was reduced
expression of CCR7+ and CXCR3+CD4 T and CD8 T cells and
fewer central memory CD4+ T cells (Fig. 4c), suggesting that
pathologic (i.e., CXCR3+) T cells are not recruited in the KO
recipients. On diabetes antigen-(IGRP) specific T cells in the
pLNs (Fig. 3c), we likewise found reduced expression of CXCR3.
Other activation markers like CD44 and PD1 were similar
between KO vs WT recipients (Fig. 4d).
β cells lacking Tet2 show reduced inflammatory responses. The
differences in WT and KO β cells might affect the infiltrating
immune cells. Therefore we compared β cells (Zn+ TMRE+)
from the WT or KO BMT recipients 8 weeks after WT transplant
and analyzed the cells by RNA-seq. About 333 genes were found
to be differentially expressed between KO and WT β cells
(p < 0.05 after FDR correction (Supplementary Fig. 6)), and 199
of these genes showed ≥1.5-fold change in expression (Fig. 5a, b).
We identified a number of differences in pathways associated
with β cell death and immune protection. These included reduced
PTEN signaling (p= 0.00129)25,26, inflammatory mediators (Irf8
and Tifa), attenuated immune signaling (Pik3cd and Abl2), and
cytokine-inducible genes (Gbp2, Gbp6, Ifi47, and Tnfaip2). Genes
involved in Class I and II MHC expression were reduced but the
levels of Class I MHC were not reduced by FACS on β cells from
Tet2-KO mice (Supplementary Fig. 7). Meanwhile, β cells from
KO recipients expressed genes associated with immune sup-
pression (GABA receptor A (Gabrg3)27, Gad2, Cd1428, and H2-
Q7 (Qa-2)14,15 (Fig. 5a, b). Compare to WT β cells, there were
changes in the expression of genes related to improved β cell
fitness (Slc39a4, Tgfbr2, Fgfr2, Fgfr3, and Aldh1a3)29–32 and
survival (Gas6, Ptpn13, and Tnfrsf19)33–37 (Fig. 5a, b).
To understand the action of Tet2 in β cells, we performed
ATAC-seq on the same β cell samples analyzed by RNA-seq in
Fig. 5a, b. We identified 60,449 open chromatin sites among the
five samples profiled. Accessibility at the overwhelming majority
of these sites (~97%) did not differ substantially between WT and
Tet2-KO cells, suggesting that Tet2 deficiency does not lead to
widespread chromatin remodeling of β cells. About 715 sites
(~1%) had greater accessibility in KO’s (FC >1.5) and 1387 (~2%)
had lower accessibility (FC <−1.5) in Tet2-KO vs WT cells
(Fig. 5c). Using HOMER transcription factor (TF) motif
enrichment analysis, 97 TF motifs were enriched in peaks with
lower accessibility (closing peaks) in KO β cells (q value <0.05)
(Supplementary Table 2). Interestingly, motifs for 15 TFs
mediating inflammatory responses such as Stats 1, 3, 4, and 5
and Irfs 1, 2, 4, and 8 (Fig. 5d) were specifically enriched in
closing peaks, suggesting that inflammatory stress-responsive cis-
regulatory elements are epigenetically decommissioned in Tet2-
deficient β cells. Fifteen TF motifs were identified as enriched in
peaks with higher accessibility (opening peaks) in KO β cells (q
value <0.05). Most of these corresponded to TFs controlling islet
β cell identity and function such as Foxa1, Foxa2, and Rfx and
were also enriched in closing peaks in KO β cells (Supplementary
Table 3), indicating that Tet2 deficiency results in opening and
closing of a subset of islet TF binding sites.
To confirm these findings and the responses of β cells to
inflammatory mediators, we first screened inducible cytokines
and chemokines in islets following IFNγ with or without
TNFα+ IL-1β. Il6, Cxcl10, Cxcl16, Ccl2, as well as Tnf were
induced by this cytokine cocktail (TNFα+ IL-1β+ IFNγ) but not
Ccl12, Ccl19, or Il1b (Supplementary Fig. 8a).
Previously Xu et al. described impaired STAT1 signaling in
tumor cells cultured with IFNγ18. Similarly, we identified reduced
IFNγ response measured by the production of Cxcl10, Cxcl11 as
well as the expression of Pdl1 but not Cxcl9 in KO vs WT islets
from B6 mice (Supplementary Fig. 8b). We cultured WT and KO
islet cells with TNFα+ IL-1β+IFNγ and found in Tet2-KO islets
reduced induction of Il6, Ccl2, Cxcl10, Cxcl16, and Tnf, which
have been linked to β cell destructive processes (Fig. 6a). Islets
from WT or KO B6 mice were used to avoid any immune cell
effects. In addition, we found that the expression of genes
associated with β cell death such as Fas, Tnfsf10b (TRAIL-R2),
and Stat138,39 were also reduced in cultured KO β cells (Fig. 6b).
DNA from β cells were recovered from KO and WT BMT
recipients and the enrichment of 5-hydroxymethylcytosine
(5hmC) on the promoter regions (500 bp within TSS that
contains multiple CpG sites) of genes measured in Fig. 6a, b
was compared. Promoter regions of Il-6, Cxcl10, Cxcl16, Fas, and
Stat1 show reduced 5hmC levels in KO vs WT β cells (Fig. 6c).
When human islets were cultured with cytokines, we found a
similar reduction of chemokine, cytokines as well as death
receptors as seen in the mouse experiment when TET2 inhibitor
R-2HG40,41 was added to the culture (Fig. 6d).
Finally, to determine whether these differences in inflamma-
tory responses are associated with β cell survival, we transferred
splenocytes from diabetic NOD mice into irradiated WT and KO
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Fig. 4 T cells from Tet2-KO islets are less activated and show reduced pathogenic phenotypes. a Volcano plot showing transcription differences in islets
infiltrates between KO and WT recipients of WT bone marrow. Eight weeks post-BMT, CD45+ islets infiltrates were sorted from KO vs WT recipients and
used subsequently for transcription analysis with NanoString Pan-Immunology panel. The data were analyzed with nSolver4.0 analysis software. 189 of
770 genes that were found to be different between infiltrates from WT and KO recipients are shown (after FDR correction, p < 0.05). Genes that are
associated with T cell activation, cell function as well as cell death are highlighted with different colors among the 189 genes. Data were from six KO vs six
WT samples that were pooled from nine KO and eight WT mice, respectively. b, c FACS analysis of CD45+ cells from pancreatic lymph nodes (pLNs) from
KO or WT BMT recipients. The % of CD45+ cells is shown. (Treg=CD4+ CD25+ CD127lo, TCM=CD44+ CD62Lhi, TEM= CD44+ CD62Llo). Data
were from four–five experiments with pLNs from individual mice. The box indicates 25–75%. The whiskers show the minima to the maxima values and the
central line indicates the median. Statistical analysis was performed using two-way ANOVA with Sidak’s multiple comparisons test (WT: n= 11 in (b), 12 in
(c); KO: n= 14 in b, 11 in c). d FACS analysis of the activation status of NRPV7 tetramer-positive IGRP-reactive CD8+ T cells from pLNs of KO and WT
BMT recipients. Data were from three independent experiments and each data point represents an individual mouse. Statistical analysis was performed
using two-way ANOVA with Sidak’s multiple comparisons test.
Table 1 Diseases and bio functions identified by Ingenuity Pathway Analysis of Nanostring data.
Diseases and disorders p value range #Molecules
Inflammatory response 1.22E-04 – 9.69E-49 91
Immunological disease 8.60E-05 – 2.59E-26 44
Molecular and cellular functions p value range #Molecules
Cellular-to-cell signaling and interaction 1.22E-04 – 9.69E-49 86
Cellular function and maintenance 1.22E-04 – 1.43E-45 85
Cellular development 1.22E-04 – 1.58E-42 82
Cellular growth and proliferation 1.22E-04 – 1.58E-42 84
Cellular movement 1.22E-04 – 8.71E-41 62
Physiological system development and function p value range #Molecules
Immune cell trafficking 1.22E-04 - 9.69E-49 90
Lymphoid tissue structure and development 1.22E-04 - 1.58E-42 92
Top canonical pathways p value Overlap
Th1 and Th2 activation pathway 9.14E-21 15.2% 23/151
Th1 pathway 8.92E-19 18.1% 19/105
Diseases and bio functions identified by Ingenuity Pathway Analysis of PanCancer Immune Profiling Data. CD45+ infiltrates were sorted from KO vs WT recipients 8 weeks post-BMT from WT NOD
BM donors (n= 13–16 KO or WT mice over six separate sortings). About 9000–45,000 cells were lysed for each reaction. Results were summarized into different disease and bio functions (marked in
bold). The name of the specific pathway was listed as well as the P value and number of molecules involved in each pathway.
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recipients and followed them for the development of diabetes.
The median time to hyperglycemia was 9.5 weeks in the WT
recipients whereas none of the six KO recipients developed
diabetes for more than 20 weeks after adoptive transfer
(p= 0.0041) (Fig. 6e).
Discussion
We have shown that TET2 can control immune-mediated
destruction of human and murine β cells through the interac-
tions with immune cells and β cell-intrinsic mechanisms. Tet2
expression is increased during the progression of diabetes in islet
cells and in β cells. However, a subpopulation of β cells that we
previously showed was protected from autoimmune killing, has
lower levels of Tet2 expression. In human pancreases, β cells also
express TET2 under inflammatory conditions, but islets from
normal individuals and from patients with long-standing T1D
have β cells without detectable TET2 expression. Our findings
indicate that TET2 is associated with, but not sufficient for, killing
of β cells, since we also found increased TET2 expression in β cells
from patients with autoimmune pancreatitis who do not develop
diabetes. Instead, our studies in Tet2-KO mice indicate that in the
absence of Tet2, β cells are protected from immune-mediated
killing. We used three complementary model systems: BM
transplantation, islet transplantation, and adoptive transfer of
diabetogenic splenocytes to identify the interactive relationships
between Tet2 expression in β cells and immune cells and show
that Tet2-KO islets are resistant to killing even in the presence or
transfer of diabetogenic T cells. The Tet2-KO β cells show tran-
scriptional differences, compared to WT in responses to inflam-























































































































Fig. 5 β cells lacking Tet2 have reduced inflammatory responses. a Volcano plot showing gene expression differences in β cells from KO vs WT recipients
of WT bone marrow. Eight weeks after the bone marrow transfer, β cells that are TMRE+ Zinc+ were sorted from KO vs WT recipients and subjected to
the cDNA library preparation and bulk RNA-seq analysis. There are 333 differentially expressed genes in total with p < 0.05 after FDR correction, and 199
with fold change >1.5 that are shown in a. Genes of particular interest are color-coded in a and b according to their function. c Comparison of ATAC-seq
profiles identify chromatin accessibility changes in β cells from KO vs WT recipients of WT bone marrow. Of 60,449 accessible sites identified across the
five samples, 715 (~1%) had increased accessibility (FC >1.5) and 1387 (~2%) had reduced accessibility in (FC <−1.5) in KO’s, respectively. d HOMER motif
analysis identified 97 TF motifs enriched in peaks with decreased accessibility (closing peaks) in KO β cell samples (q value <0.05), 15 of which are
inflammatory mediators. The rank of the 97 TF motifs was sorted by q value. Data were from three sortings and three–four mice per group per sorting.
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function, survival, and immune suppression, and reduced
expression of genes associated with immune responses and acti-
vation. Importantly, there was also reduced chromatin accessi-
bility at putative regulatory elements containing binding motifs of
inflammatory mediators in Tet2-KO β cells. These molecular
changes were confirmed by functional studies that showed
reduced secretion of cytokines and chemokines when the Tet2-
KO islets were cultured with inflammatory cytokines. As a result,
Tet2-KO islets fail to activate immune responses and autoreactive
T cells, resulting in reduced autoimmune elimination of Tet2-KO
ß cells compared to WT. In summary, our studies have identified
a mechanism that controls interactions between β cells and
Fig. 6 Tet2-KO ß cells show reduced inflammation response in vitro and are resistant to killing by diabetogenic cells in vivo. Transcription analysis of
cytokines and chemokines (a) as well as cell death receptors (b) in KO vs WT islets from B6 mice following culture with the indicated cytokines for 24 h.
Data were mean ± SD of three–four independent experiments, four mice per group per experiment. Statistical analysis was performed using a two-tailed
unpaired t-test without correction for multiple comparisons. c Enrichment of 5hmC at the promoter regions of indicated genes was examined by hMeDIP-
qPCR. Comparisons were made between β cells from KO vs WT NOD recipients of WT NOD bone marrow. Data were mean ± SD of three independent
experiments, three–five mice per group per experiment. Statistical analysis was performed using a two-tailed unpaired t-test without correction for multiple
comparisons. d Transcription analysis of the genes studied in (a and b) in human islets after culture with TNFα+IL-1β+ IFNγ with or without TET inhibitor
R-2HG for 24 h. The Ct of cytokine group with or without R-2HG was compared to islets in media supplemented with or without R-2HG, respectively. Data
(mean ± SD) were from three experiments, each with 4000–8000 islet equivalency (IEQ) from each nondiabetic donor. Statistical analysis was performed
using a two-tailed unpaired t-test without correction for multiple comparisons. e Diabetes incidence in Tet2-WT or KO NOD mice that received by
adoptive transfer 1.5 × 107 diabetogenic splenocytes from diabetic WT NOD mice after half lethal dose irradiation (650 rads). Mice were followed up to
21 weeks post adoptive transfer. Statistical analysis was performed using Log-rank curve comparison. n= 6 for each group.
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immune cells that leads to immune-mediated killing and suggest
that inhibiting this pathway may lead to improved survival of β
cells in the setting of autoimmunity.
In human pancreatic sections, we found differences in TET2
expression within islet cells and between pancreases from indi-
viduals with different stages of β cell destruction. We found
expression in both the nuclear and cytoplasm, consistent with
reports in neurons42. In patients with long-standing T1D, the
absence of TET2 expression suggests an association with β cell
survival or possibly β cells that do not respond to inflammatory
mediators.
Our studies of the control of β cell responses by Tet2 provide
insight into the mechanisms that account for these histologic
findings. A fully pathologic autoimmune repertoire developed in
the Tet2-KO recipients of WT BM. However, these cells did not
receive the same activation signals and did not cause β cell killing
as shown by our analysis of their transcriptome, when compared
to islet infiltrates from the WT BMT recipients. The absence of
TET2 expression on β cells, therefore, could potentially explain
the ability of some β cells to survive even when autoreactive
T cells remain in the host. The Tet2-KO BM recipients developed
diabetogenic T cells since splenocytes were able to transfer dia-
betes to NOD/scid recipients at a rate similar to WT cell donors.
Consistent with these findings, islets from the Tet2-KO mice
showed significantly delayed rejection compare to islets from WT
donors when they were transplanted into WT NOD recipients.
Even in the same mouse, the WT but not KO islets were pre-
ferentially destroyed.
Tet2 deficiency may affect the survival of β cells through direct
or indirect pathways. ATAC-seq revealed reduced chromatin
accessibility in Tet2-deficient ß cells at putative binding sites for
Stat and Irf TFs that have been associated with cytokine signaling.
Gene expression may occur from local epigenetic modifications
and therefore decreased expression is expected with Tet2
deficiency43. Previous studies of Tet2-deficient tumor cells iden-
tified impaired STAT1 signaling that prevented the expression of
chemokines and PD-L1 expression and enabled tumors to evade
anti-PD-L1 immune therapy18. These investigators described a
disrupted IFNγ-JAK-STAT signaling cascade in Tet2-deficient
tumor cells that we also found with β cells.
These observations indicate that the islet cells themselves
deliver signals to the autoreactive immune cells that leads to their
activation and β cell killing. These signals most likely are the
result of differences in the Tet2-KO β cells since the antigen-
presenting cells in the transplant recipients were from the WT
BM donor. Our data, in Supplementary Fig 8, show that IFNγ
inducible chemokines (CXCL10 and CXCL9), as well as PD-L1,
are reduced in the KO β cells, consistent with the inaccessibility of
STAT1 signaling (Fig. 5d). Groom et al. described a CXCR3
inflammatory loop in which the IFNγ-induced chemokines
recruit CXCR3-expressing T cells to inflammatory sites44. The
production of IFNγ by the CXCR3+ T cells can provide a “feed
forward” in which additional CXCR3-expressing inflammatory
cells, such as those thought to mediate autoimmune diabetes are
recruited. Thus, the inability to respond to IFNγ may block this
loop and result in the reduced frequency of the pathologic
T cells23,45–48. A unique feature of this mechanism of protection
is that it does not dependent on the specificity or the ability of the
immune cells to respond to the target β cells per se but rather on
the ability of the β cells to respond to inflammatory mediators
and recruit and activate the T cells. In addition, as a result of the
loss of Tet2, islet cells express reduced levels of molecules that are
directly responsible for killing including Fas and Tnfrsf10b.
In addition to the participation of the β cells in immune cell
interactions, we also identified intrinsic pathways to account for
enhanced β cell survival in Tet2-KO β cells. We found improved
survival when β cells were cultured with inflammatory cytokines
as well as infiltrating immune cells, both of which may mediate β
cell killing. In the Tet2-KO β cells, expression of GABA receptor
A (Gabrg3), which is associated with immune suppression, was
reduced and there was increased expression of Tnfrsf19, Fgfr2,
and Fgfr3. Increased Tnfrsf19 expression was shown to attenuate
TNFβR signaling and improve β cell survival29,30. Fgfr2 and Fgfr3
are growth factor receptors, and attenuation of FGF signaling by
expressing dominant-negative forms of the FGFRs receptors in
mouse β cells leads to diabetes31. Gas6, which is linked to β cell
proliferation, was also increased in the expression on the KO β
cells49. These cell-intrinsic mechanisms may account for the
resistance of the cells to killing by inflammatory cytokines in the
absence of extrinsic cells.
There are a number of limitations of our studies. First, TET2
loss of function mutations occurs frequently in humans18.
Therefore, the applicability of our findings in the inbred NOD
mouse needs further confirmation. Moreover, some have ques-
tioned the model’s relevance to human disease since there are a
number of nonspecific interventions that may modulate sponta-
neous diabetes in this model50. Tet2 causes demethylation of
methylcytosines, and therefore the relationship between the loss
of this enzymatic activity and decreased transcription of genes is
somewhat paradoxical. However, our previous studies showing
increased activity of Dnmts suggest a mechanism that, if unop-
posed, could lead to these outcomes51. In our Tet2-deficient NOD
mice and recipients of bone marrow transplants (BMTs), Tet2
was absent throughout the development of immune cells. We do
not know if there is a critical time(s) when Tet2 expression is
involved in β cell killing as well as immune activation but our
adoptive transfer studies with diabetogenic T cells would suggest
that absence of Tet2 can be protective even when β cells are
attacked by fully matured effector cells. In addition, the rela-
tionship, particularly in human tissues, between the autoreactive
repertoire, TET2 expression, and β cell killing will require further
studies with human β and effector T cells. Lastly, there may be an
effect of other environmental factors, on the activation of T cells
in the Tet2-deficient mice, such as the microbiome that may affect
their activation52.
In summary, our studies have identified an interaction between
β cells and immune cells that regulates immune cell activation,
recruitment, and killing. Expression of Tet2 is required for β cells
to produce chemokines and cytokines that are needed for the
activation and pathologic function of diabetogenic T cells. In its
absence, β cells resist cell- or cytokine-mediated killing even when
potentially autoreactive cells are present through cell-intrinsic
mechanisms as well as avoiding activation of immune cells. These
studies suggest a potential future strategy to protect insulin-
producing cells from immune-mediated killing in the setting of
autoimmunity or even for engineering more resilient and/or
resistant β cell replacements to avoid recurrent immune
elimination.
Methods
Mice. C57BL/6Tet2−/− male breeder under B6 background was purchased from
The Jackson lab and backcrossed with NOD females for over 14 generations.
Female NOD, B6, and NOD/scid mice were also obtained from The Jackson
Laboratory and maintained under pathogen-free conditions. All protocols were
approved by the Yale Institutional Animal Care and Use Committee. Animals were
housed under the following facility conditions: Temperatures: 21–23 °C; Humidity:
50–60%. Lighting: 12:12 (i.e., 12 h of light from 7 a.m.–7 p.m. then 12 h of dark
from 7 p.m.–7 a.m.).
Intraperitoneal glucose tolerance test (IPGTT). B6 Tet2-WT, HET, and KO
mice fasted for 16 h. Blood glucose levels were measured 0, 15, 30, 60 and 120 min
after glucose injection (2 g/kg body weight). IPGTT result was presented as the area
under the curve using trapezoidal rule53 and then divide by the total assay time
(120 min).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25367-z
10 NATURE COMMUNICATIONS |         (2021) 12:5074 | https://doi.org/10.1038/s41467-021-25367-z | www.nature.com/naturecommunications
Human islets and pancreas tissues. Human islet samples were obtained from
adult, nondiabetic organ donors from the Prodo Labs (details listed in Supple-
mentary Table 1). Pancreas tissues from donors with autoimmune pancreatitis
(n= 5) or chronic pancreatitis (n= 3) were obtained from the Department of
Pathology at Yale and histologic slides of the pancreas were obtained from normal
individuals (n= 8), nondiabetic donors who were autoantibody+ (n= 7), and C-
peptide+ patients with T1D of relatively short duration (n= 7) from nPOD. The
use of human tissues and islets was considered “not human subjects research” as
per institutional policies (Yale Institutional Review Board). It did not involve data
obtained through intervention or interaction with the individual and did not
contain identifiable private information.
Immunofluorescent labeling of human pancreas. To identify TET2 protein
expression in pancreatic islet cells, formalin-fixed, paraffin-embedded sections (5-
μm thickness) of human pancreas were incubated with primary antibodies against
TET2 (Abcam, cat# 230358), insulin (DAKO, cat# A0564), and CD45 (DAKO,
clone# 2B11+ PD7/26) overnight at 4 °C, washed and processed with the appro-
priate secondary fluorescent-conjugated antibodies. Subsequently, sections were
dyed with 0.7% Sudan Black and CuSO4 to quench auto-fluorescence and coun-
terstained with DAPI54. Images were acquired on an UltraVIEW VoX (Perki-
nElmer) spinning disc confocal Nikon Ti-E Eclipse microscope using the Volocity
6.3 software (Improvision). Image J was used to quantify the fluorescence intensity
of TET2 staining in the islets in different clinical conditions. Twenty islets were
picked per condition was from three–seven donors.
Mouse islet isolation and β cell staining and purification. Mouse islets were
handpicked with a stereomicroscope after collagenase digestion of pancreases and
single-cell suspensions were prepared15,17. For β cell enrichment, single islet cells
were stained with TMRE and FluoZin-3 and sorted with a FACSAria II (BD). In
some experiments, intracellular staining with anti-insulin (R&D Systems, Clone #
182410), anti-Tet2 (Cell Signaling Technologies, clone# D6C7K), and anti-
glucagon (Abcam, clone# K79bB10) was used at 2.5 mg/ml to identify β cells or α
cells and analyzed or sorted with an LSRFortessa (BD).
Flow cytometry on immune cells. For standard surface staining, lymphocytes (106
cells/sample) were washed with PBS and incubated for 30 min at 4 °C (dark) in
100 µl PBS plus 2% FBS with indicated fluorochrome-labeled monoclonal anti-
bodies. After washing with PBS two times, 30,000–50,000 live cells were analyzed
by flow cytometry. For surface staining, CD45 (clone# 30-F11, cat#103125), CD4
(clone#GK1.5, cat#100411), CD8 (clone#53-6.7, cat#100727), CD25 (clone#3C7,
cat#101903), CD69 (clone#H1.2F3, cat#104505), CXCR3 (clone#CXCR3-173,
cat#126535), CCR7 (clone#4B12, cat#120113), CD44 (clone#IM7,cat#103015), and
CD62L (clone#MEL-14, cat#104407) were diluted to a working concentration of
2 mg/ml. All antibodies were from BioLegend. Gating strategies are included as
Supplementary Fig. 9.
Islet cultures. Human or mouse islets were rested upon arrival or isolation in
complete RPMI media for 3 h before aliquoting (100 per well) into a non-treated
24-well plate and culture for 18–24 h with or without cytokines. All mouse and
human cytokines were used at 10 ng/ml, except for human IL-6 at 20 ng/ml and
human IL-17A at 50 ng/ml. TET inhibitor R-2HG was used at 400 nM. The cells
were then harvested for RNA extraction and transcriptional analysis of genes of
interest. In cytokine or immune cell-mediated killing experiments, mouse islets
were dispersed with accutase and cultured as single cells overnight before harvest
for live/dead analysis by flow or cell death receptors analysis by qRT-PCR.
Adoptive transfer of diabetogenic splenocytes. Tet2-KO or WT NOD mice
(8 weeks of age) were irradiated with a split dose (2 × 325 rads, 2–3 h apart, 650
rads total) and splenocytes (1 × 107) from a WT NOD mouse with recent-onset
DM were transferred i.p. within 3 h of irradiation. The time to diagnosis of diabetes
(i.e., glucose >250 mg/dl × 2) was recorded after the adoptive transfer.
Streptozotocin (STZ) treatment. Eight to 10-week-old Tet2-WT and KO B6 mice
were given a single dose of STZ (200 mg/kg, i.p) and followed daily following the
treatment.
Bone marrow transplant (BMT). For BMTs, donor WT NOD mice 6–8 weeks of
age were euthanized by CO2. BM was flushed with ice-cold HBSS and the ery-
throcytes were removed by lysis. The recipient KO or WT mice (4–8 weeks of age)
were irradiated with split dose (2 × 550 rads, 2–3 h apart, 1100 rads total) and
donor BM (10 × 106 cells) transferred i.v. within 3 h of irradiation55. Recipients
were followed for hyperglycemia (glucose >250 mg/dl × 2) and diabetic incidence
was recorded at the time after BMT.
Islet transplant. About 250–300 handpicked islets were pooled from 5–6 weeks
KO or WT donors (two–three donors per recipient). They were transplanted under
the kidney capsule of WT NOD recipients (6 weeks of age). Two weeks later,
diabetogenic splenocytes were given i.p.to the transplant recipients (1 × 107 cells
per recipient). Blood glucose was measured twice weekly and diabetes incidence
was followed and recorded at the age of islets recipients.
Low-input RNA-seq and data analysis. Viable β cells were enriched by FACS
sorting from KO or WT recipients 8 weeks post-BMT from WT BM donors. RNA
was extracted and reverse transcription and cDNA amplification were performed
using 10 ng of RNA using the SMARTer Ultra Low RNA kit (Clontech Labora-
tories) as previously reported15. Sequencing libraries were prepared using the
Nextera XT DNA Sample Preparation kit (Illumina). Libraries from eight samples
were pooled and sequenced with a 2 × 100 bp paired-end protocol on the HiSeq
4000 Sequencing System (Illumina), occupying half a lane with ~300 million reads.
The sequencing was done at the Yale Stem Cell Center Genomics Core. The reads
were mapped to mouse reference transcriptome mm9 and mRNA was quantified.
RNA-Seq data were analyzed with Partek Flow software (v6.6).
NanoString Pan-Immunology Panel Analysis of islet infiltrates. Analysis was
done with the NanoString Technologies Pan-Immunology panel as per the man-
ufacturer’s instructions. Briefly, 9000–45,000 CD45+ islet infiltrates were sorted
from KO or WT BMT recipients and cell pellets were lysed in 33% RLT lysis buffer
(QIAGEN). Up to 3.5 μl lysate was used directly in a 15 μl hybridization reaction
which was kept at 65 °C for 24 h. The hybridization product was prepped and used
with the digital analyzer nCounter MAX/FLEX system. The data were analyzed
with nSolver4.0 analysis software (NanoString Technologies). Differentially
expressed genes (P value <0.05 after FDR correction) were identified and pathways
were analyzed with IPA and upstream regulator analysis (https://
www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/).
RNA extraction and RT-PCR analysis. RNA was extracted with RNeasy Plus Mini
Kit (QIAGEN, cat#74134), and the High-Capacity cDNA Reverse Transcription
Kit was used for cDNA synthesis (Applied Biosystems, cat#4368814). Primer pairs
were used in this study together with a QuantiFast SYBR Green PCR kit (QIA-
GEN). The sequences of primer pairs used in this study are listed in Supplementary
Table 4. The Actb housekeeping gene was used to normalize the input RNA in all
real-time qPCR assays. Gene expression is presented as Delta Ct= (Ct of Actb− Ct
of target gene)+ 20 or in other cases as relative fold to control. In Supplementary
Fig. 1e, RNA was recovered from perm/fixed cells with RecoverAll™ Total Nucleic
Acid Isolation Kit for FFPE (Invitrogen, AM1975). Taqman probes were used in
qPCR15.
ATAC-seq and data analysis. ATAC-seq libraries were prepared from FACS
sorted mouse islet β cells56. After wash and lysis, the cell pellet was resuspended in
50 ul of transposition mixture (Illumina Tagment DNA TDE1 Enzyme and Buffer)
and incubated for 30 min at 37 °C. Transposed DNA was cleaned with a Qiagen
MinElute kit and stored frozen at −20 °C until indexing as decribed57. Libraries
were sequenced on an Illumina NovaSeq S1 with 2 × 101 bp cycles. Raw sequence
reads were quality trimmed using Trimmomatic version 0.3258 with the following
parameters “TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:36.” Trimmed reads
were aligned to the mouse genome (mm10) using BWA version 0.7.1259, specifi-
cally using the bwa mem –M option. Duplicate reads were marked and removed
using “MarkDuplicates” from Picard-tools version 1.95 (http://
broadinstitute.github.io/picard/). The quality of aligned reads was examined using
Ataqv v.1.0.060. After preprocessing and quality filtering, peaks were called on
alignments with MACS version 2.1.0.2015122261 using the parameters “-p 0.0001
-g mm -f BAMPE -nomodel -nolambda -B -keep-dup all -call-summits”. Peaks
located in blacklisted regions of the genome were removed. Overlapping peaks
from all samples were merged with BEDTools version 2.26.062 resulting in 60,449
consensus peak regions. Raw read counts in these peaks for each sample were
determined using the R package DiffBind_2.4.863. To identify peaks with differing
chromatin accessibility between WT and KO samples, the log mean normalized
reads (log2 counts per million) were compared between the two sample groups.
Peaks with a differing accessibility >1.5-fold in either group were used for TF motif
enrichment analysis. The HOMER suite version 4.664 and “findMotifsGenome.pl”
script with parameters “mm10 -size 200” was used to determine TF motifs enriched
(q value <0.05) in the peaks of interest.
Hydroxymethylated DNA immunoprecipitation and qPCR. The experiments
were carried out using the hMeDIP kit (Active Motif, 55010) according to the
manufacturer’s instructions. Briefly, β cells were enriched from islets 8 weeks after
BMT for genomic DNA recovery with the DNeasy Blood & Tissue Kit (QIAGEN,
69504), followed by digestion using restrictive enzyme Mse I (NEB, R0525S).
Digested DNA was purified through with DNA purification column (Qiagen,
28104). Purified DNA (1 μg) was immunoprecipitated with 2.5 μg of mouse anti-
5hmC antibody from the kit and was incubated overnight at 4 °C. The magnetic
beads were added to the DNA–antibody mixture for 2 h incubation at 4 °C and
isolation of immunoprecipitated DNA was performed according to the kit
instructions. SYBR® Green Supermix (Bio-Rad) on a Bio-Rad CFX96 Real-Time
system was used to perform qPCR, as indicated by the manufacturer’s protocol.
Eluted DNA was undergone qPCR as template and primers adjacent (500 bp to the
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transcription starting site (TSS)) to the promoter regions of target genes was used
for amplification to analyze the changes in the local 5hmC signal in the respective
promoter regions. The Ct values of each sample were used in the post-PCR data
analysis. The relative enrichments (after normalization against control IgG) of the
indicated DNA regions were calculated using the Percent Input (10% of the total
DNA used in the reaction) Method according to the manufacturer’s instructions.
Statistical analysis. The number of samples per group and experiment repeats, as
well as the statistical tests used, is indicated in each figure legend.
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The ATAC-seq and RNA-seq data that support the findings of this study have been deposited
in NCBI BioProject (https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA630597) with the
accession code PRJNA630597. All other data are available from the corresponding author
upon reasonable request. Source data are provided with this paper.
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